1
|
Kumar S, Riisom M, Jamieson SMF, Kavianinia I, Harris PWR, Metzler-Nolte N, Brimble MA, Hartinger CG. On-Resin Conjugation of the Ruthenium Anticancer Agent Plecstatin-1 to Peptide Vectors. Inorg Chem 2023; 62:14310-14317. [PMID: 37611203 DOI: 10.1021/acs.inorgchem.3c01718] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 08/25/2023]
Abstract
Ruthenium piano-stool complexes have been explored for their anticancer activity and some promising compounds have been reported. Herein, we conjugated a derivative of plecstatin-1 to peptides in order to increase their cancer cell targeting ability. For this purpose, plecstatin-1 was modified at the arene ligand to introduce a functional amine handle (3), which resulted in a compound that showed similar activity in an in vitro anticancer activity assay. The cell-penetrating peptide TAT48-60, tumor-targeting neurotensin8-13, and plectin-targeting peptide were functionalized with succinyl or β-Ala-succinyl linkers under standard solid-phase peptide synthesis (SPPS) conditions to spatially separate the peptide backbones from the bioactive metal complexes. These modifications allowed for conjugating precursor 3 to the peptides on resin yielding the desired metal-peptide conjugates (MPCs), as confirmed by high-performance liquid chromatography (HPLC), NMR spectroscopy, and mass spectrometry (MS). The MPCs were studied for their behavior in aqueous solution and under acidic conditions and resembled that of the parent compound plecstatin-1. In in vitro anticancer activity studies in a small panel of cancer cell lines, the TAT-based MPCs showed the highest activity, while the other MPCs were virtually inactive. However, the MPCs were significantly less active than the small molecules plecstatin-1 and 3, which can be explained by the reduced cell uptake as determined by inductively coupled plasma MS (ICP-MS). Although the MPCs did not display potent anticancer activities, the developed conjugation strategy can be extended toward other metal complexes, which may be able to utilize the targeting properties of peptides.
Collapse
Affiliation(s)
- Saawan Kumar
- School of Chemical Sciences, University of Auckland, Private Bag 92019, Auckland 1142, New Zealand
- School of Biological Sciences, University of Auckland, Private Bag 92019, Auckland 1142, New Zealand
| | - Mie Riisom
- School of Chemical Sciences, University of Auckland, Private Bag 92019, Auckland 1142, New Zealand
- Auckland Cancer Society Research Centre, University of Auckland, Private Bag 92019, Auckland 1142, New Zealand
| | - Stephen M F Jamieson
- Auckland Cancer Society Research Centre, University of Auckland, Private Bag 92019, Auckland 1142, New Zealand
| | - Iman Kavianinia
- School of Biological Sciences, University of Auckland, Private Bag 92019, Auckland 1142, New Zealand
| | - Paul W R Harris
- School of Chemical Sciences, University of Auckland, Private Bag 92019, Auckland 1142, New Zealand
- School of Biological Sciences, University of Auckland, Private Bag 92019, Auckland 1142, New Zealand
| | - Nils Metzler-Nolte
- Faculty of Chemistry and Biochemistry, Ruhr University Bochum, Bochum 44801, Germany
| | - Margaret A Brimble
- School of Chemical Sciences, University of Auckland, Private Bag 92019, Auckland 1142, New Zealand
- School of Biological Sciences, University of Auckland, Private Bag 92019, Auckland 1142, New Zealand
| | - Christian G Hartinger
- School of Chemical Sciences, University of Auckland, Private Bag 92019, Auckland 1142, New Zealand
| |
Collapse
|
2
|
Linares J, Varese M, Sallent-Aragay A, Méndez A, Palomo-Ponce S, Iglesias M, Batlle E, Pisonero J, Montagut C, Giralt E, Lo Re D, Calon A. Peptide-Platinum(IV) Conjugation Minimizes the Negative Impact of Current Anticancer Chemotherapy on Nonmalignant Cells. J Med Chem 2023; 66:3348-3355. [PMID: 36808993 DOI: 10.1021/acs.jmedchem.2c01717] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/23/2023]
Abstract
The relative success of platinum (Pt)-based chemotherapy comes at the cost of severe adverse side effects and is associated with a high risk of pro-oncogenic activation in the tumor microenvironment. Here, we report the synthesis of C-POC, a novel Pt(IV) cell-penetrating peptide conjugate showing a reduced impact against nonmalignant cells. In vitro and in vivo evaluation using patient-derived tumor organoids and laser ablation inductively coupled plasma mass spectrometry indicates that C-POC maintains robust anticancer efficacy while displaying diminished accumulation in healthy organs and reduced adverse toxicity compared to the standard Pt-based therapy. Likewise, C-POC uptake is significantly lowered in the noncancerous cells populating the tumor microenvironment. This results in the downregulation of versican, a biomarker of metastatic spreading and chemoresistance that we found upregulated in patients treated with standard Pt-based therapy. Altogether, our findings underscore the importance of considering the off-target impact of anticancer treatment on normal cells to improve drug development and patient care.
Collapse
Affiliation(s)
- Jenniffer Linares
- Cancer Program, Hospital del Mar Medical Research Institute (IMIM), 08003 Barcelona, Spain
| | - Monica Varese
- Department of Chemistry, Institute for Research in Biomedicine (IRB Barcelona), The Barcelona Institute of Science and Technology (BIST), 08028 Barcelona, Spain
| | - Anna Sallent-Aragay
- Cancer Program, Hospital del Mar Medical Research Institute (IMIM), 08003 Barcelona, Spain
| | - Ana Méndez
- Scientific and Technological Resources (SCTs), University of Oviedo, 33600 Mieres, Spain
| | - Sergio Palomo-Ponce
- Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), 28029 Madrid, Spain.,Department of Cancer, Institute for Research in Biomedicine (IRB Barcelona), The Barcelona Institute of Science and Technology (BIST), 08028 Barcelona, Spain
| | - Mar Iglesias
- Cancer Program, Hospital del Mar Medical Research Institute (IMIM), 08003 Barcelona, Spain.,Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), 28029 Madrid, Spain.,Pathology Department, Hospital del Mar, 08003 Barcelona, Spain
| | - Eduard Batlle
- Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), 28029 Madrid, Spain.,Department of Cancer, Institute for Research in Biomedicine (IRB Barcelona), The Barcelona Institute of Science and Technology (BIST), 08028 Barcelona, Spain.,Institució Catalana de Recerca i Estudis Avançats (ICREA), 08010 Barcelona, Spain
| | - Jorge Pisonero
- Department of Physics, Faculty of Science, University of Oviedo, 33005 Oviedo, Spain
| | - Clara Montagut
- Cancer Program, Hospital del Mar Medical Research Institute (IMIM), 08003 Barcelona, Spain.,Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), 28029 Madrid, Spain.,Medical Oncology Department, Hospital del Mar, 08003 Barcelona, Spain.,Universitat Pompeu Fabra, 08002 Barcelona, Spain
| | - Ernest Giralt
- Department of Chemistry, Institute for Research in Biomedicine (IRB Barcelona), The Barcelona Institute of Science and Technology (BIST), 08028 Barcelona, Spain.,Department of Inorganic and Organic Chemistry, University of Barcelona, 08028 Barcelona, Spain
| | - Daniele Lo Re
- Department of Chemistry, Institute for Research in Biomedicine (IRB Barcelona), The Barcelona Institute of Science and Technology (BIST), 08028 Barcelona, Spain
| | - Alexandre Calon
- Cancer Program, Hospital del Mar Medical Research Institute (IMIM), 08003 Barcelona, Spain
| |
Collapse
|
3
|
Song X, Li W, Xu J, Ji P, Li Y, Feng G, Wang B. Novel Aggregation-Induced Emission Fluorescent Molecule for Platinum(IV) Ion-Selective Recognition and Imaging of Controlled Release in Cells. Anal Chem 2023; 95:3883-3891. [PMID: 36745860 DOI: 10.1021/acs.analchem.2c05650] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/08/2023]
Abstract
The loading, delivery, and release of Pt(IV) precursors in living organisms are important aspects of exploring the development of platinum drugs. In recent years, the biological application of the fluorescent sensors to platinum drugs has been insufficient to meet the study of Pt(IV) precursors. It is urgent to design and develop a biocompatible, multifunctional fluorescent sensor for the study of loading, transport, and release of Pt(IV) ions. Herein, we report a fluorescent molecule (E)-6-(diethylamino)-N'-(4-(diphenylamino) benzylidene)-2-oxo-2H-chromene-3 carbohydrazide (CHTPA). CHTPA has good sensitivity and selectivity to Pt(IV) when the water content is 5%, and significant increase of the fluorescence emission intensity of CHTPA is observed with Pt(IV) concentration. The sensing mechanism is attributed to photo-induced electron transfer, which is verified by X-ray absorption near edge spectroscopy spectra, UV-vis absorption spectroscopy, 1H NMR spectra, and Fourier transform infrared spectra. Furthermore, the CHTPA-Pt(IV) complex is able to release Pt(IV) in aqueous solution, and the green fluorescence of CHTPA based on the aggregation-induced emission effect can be observed. Inspired by these, the amphiphilic block copolymer poly(ethyloxide)-block-polystyrene (PEO-b-PS) is used to prepare the nonconjugated polymer dots (Pdots). The experimental results show that Pdots can effectively slow down the release speed of Pt(IV) in aqueous solution and it has a great monodispersity in aqueous solution. Meanwhile, Pdots show low cytotoxicity, and this is favorable for intracellular applications. The investigation of cellular imaging indicates that these Pdots can act as a carrier to deliver Pt(IV) into MCF-7 cells for visualized delivery and sustained release of platinum(IV) ions. Therefore, this study provides a new avenue to design and develop a biocompatible multifunctional fluorescent sensor for studying the loading, delivery, and release of Pt(IV) in cells.
Collapse
Affiliation(s)
- Xuerong Song
- Department of Analytical Chemistry, College of Chemistry, Jilin University, Changchun130021, China
| | - Wanmeng Li
- Department of Analytical Chemistry, College of Chemistry, Jilin University, Changchun130021, China
| | - Jianing Xu
- Department of Analytical Chemistry, College of Chemistry, Jilin University, Changchun130021, China
| | - Peng Ji
- Department of Analytical Chemistry, College of Chemistry, Jilin University, Changchun130021, China
| | - Yanchun Li
- Institute of Theoretical Chemistry, College of Chemistry, Jilin University, Changchun, Jilin130023, China
| | - Guodong Feng
- Department of Analytical Chemistry, College of Chemistry, Jilin University, Changchun130021, China
| | - Bo Wang
- State Key Laboratory of Supramolecular Structure and Materials, Jilin University, Changchun, Jilin130012, China
| |
Collapse
|
4
|
Zhang QY, Yu QL, Luan WJ, Li TF, Xiao YN, Zhang L, Li Y, Rong R, Ren CG. LWJ-M30, a conjugate of DM1 and B6, for the targeted therapy of colorectal cancer with improved therapeutic effects †. RSC Adv 2023; 13:10840-10846. [PMID: 37033427 PMCID: PMC10074231 DOI: 10.1039/d2ra07758b] [Citation(s) in RCA: 2] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/05/2022] [Accepted: 03/27/2023] [Indexed: 04/09/2023] Open
Abstract
Colorectal cancer (CRC) is one of the most prevalent cancers worldwide as well as a significant cause of mortality. The conventional treatment could cause serious side effects and induce drug resistance, recurrence and metastasis of cancers. Hence, specific targeting of cancer cells without affecting the normal tissues is currently an urgent necessity in cancer therapy. The emerging of peptide–drug conjugates (PDC) is regarded as a promising approach to address malignant tumors. LWJ-M30, a conjugate of DM1 and B6 peptide, targeted transferrin receptors (TfRs) on the surface of the CRC cells, showing a powerful anti-cancer effect. LWJ-M30 significantly inhibited the HCT116 cells proliferation and migration in vitro. LWJ-M30 also dramatically decreased the level of polymeric tubulin, while the disruption of microtubules caused the cell cycle to be arrested in the G2/M phase. LWJ-M30 induced the HCT116 cells apoptosis both in vivo and in vitro. The results in vivo demonstrated that LWJ-M30 could inhibit the HCT116 growth without affecting the mouse body weight. Taking these results together, our data indicated that LWJ-M30 could improve the therapeutic effects of DM1 while reducing the systemic toxicity in normal tissues. LWJ-M30 targeted TfR, dramatically decreased the level of polymeric tubulin, while the disruption of microtubules meant the cell cycle was arrested in the G2/M phase and thus caused cells apoptosis.![]()
Collapse
Affiliation(s)
- Qiu-Yan Zhang
- Yantai Key Laboratory of Nanomedicine & Advanced Preparations, Yantai Institute of Materia MedicaShandongChina
| | - Qing-Long Yu
- Yantai Key Laboratory of Nanomedicine & Advanced Preparations, Yantai Institute of Materia MedicaShandongChina
| | - Wei-Jing Luan
- Yantai Key Laboratory of Nanomedicine & Advanced Preparations, Yantai Institute of Materia MedicaShandongChina
| | - Tong-Fang Li
- Yantai Key Laboratory of Nanomedicine & Advanced Preparations, Yantai Institute of Materia MedicaShandongChina
| | - Ya-Ni Xiao
- Yantai Key Laboratory of Nanomedicine & Advanced Preparations, Yantai Institute of Materia MedicaShandongChina
| | - Li Zhang
- Yantai Key Laboratory of Nanomedicine & Advanced Preparations, Yantai Institute of Materia MedicaShandongChina
| | - Yi Li
- Yantai Key Laboratory of Nanomedicine & Advanced Preparations, Yantai Institute of Materia MedicaShandongChina
| | - Rong Rong
- Yantai Key Laboratory of Nanomedicine & Advanced Preparations, Yantai Institute of Materia MedicaShandongChina
| | - Chun-Guang Ren
- Yantai Key Laboratory of Nanomedicine & Advanced Preparations, Yantai Institute of Materia MedicaShandongChina
- College of Life Sciences, Yantai UniversityYantai 264005China
| |
Collapse
|
5
|
Wei D, Huang Y, Wang B, Ma L, Karges J, Xiao H. Photo-Reduction with NIR Light of Nucleus-Targeting Pt IV Nanoparticles for Combined Tumor-Targeted Chemotherapy and Photodynamic Immunotherapy. Angew Chem Int Ed Engl 2022; 61:e202201486. [PMID: 35212437 DOI: 10.1002/anie.202201486] [Citation(s) in RCA: 61] [Impact Index Per Article: 30.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/26/2022] [Indexed: 12/19/2022]
Abstract
The development of PtIV prodrugs which are selectively reduced within cancerous cells into their PtII therapeutically active species has received increasing attention within the last decade. Despite recent research progress, the majority of investigated compounds are excited using ultraviolet or blue light. As the light penetration depth is low at these wavelengths, the treatment of deep-seated or large tumors is limited. To overcome this limitation, herein, the example of PtIV -functionalized nanoparticles that could be excited within the NIR region at 808 nm is reported. The polymer backbone which can self-assemble into nanoparticles was functionalized with PtIV complexes for chemotherapy, photosensitizers for photodynamic immunotherapy, and nucleus/cancer-targeting peptides. Upon irradiation, the PtIV center is reduced to PtII and the axially coordinated ligands are released, presenting a multimodal treatment. While selectively accumulating in tumorous tissue, the nanoparticles demonstrated the ability to eradicate a triple-negative breast cancer tumor inside a mouse model.
Collapse
Affiliation(s)
- Dengshuai Wei
- Beijing National Laboratory for Molecular Science, State Key Laboratory of Polymer Physical and Chemistry, Institute of Chemistry Chinese Academy of Science, Beijing, 100190, China.,University of Chinese Academy of Sciences, Beijing, 100049, China
| | - Yun Huang
- Beijing National Laboratory for Molecular Science, State Key Laboratory of Polymer Physical and Chemistry, Institute of Chemistry Chinese Academy of Science, Beijing, 100190, China
| | - Bin Wang
- Beijing National Laboratory for Molecular Science, State Key Laboratory of Polymer Physical and Chemistry, Institute of Chemistry Chinese Academy of Science, Beijing, 100190, China.,University of Chinese Academy of Sciences, Beijing, 100049, China
| | - Lili Ma
- College of Chemistry and Environmental Science, Hebei University, Baoding, 071002, China
| | - Johannes Karges
- Department of Chemistry and Biochemistry, University of California, San Diego, 9500 Gilman Drive, La Jolla, CA 92093, USA
| | - Haihua Xiao
- Beijing National Laboratory for Molecular Science, State Key Laboratory of Polymer Physical and Chemistry, Institute of Chemistry Chinese Academy of Science, Beijing, 100190, China.,University of Chinese Academy of Sciences, Beijing, 100049, China
| |
Collapse
|
6
|
Wei D, Huang Y, Wang B, Ma L, Karges J, Xiao H. Photo‐Reduction with NIR Light of Nucleus Targeting Pt(IV) Nanoparticles for Combined Tumor‐Targeted Chemotherapy and Photodynamic Immunotherapy. Angew Chem Int Ed Engl 2022. [DOI: 10.1002/ange.202201486] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/09/2022]
Affiliation(s)
- Dengshuai Wei
- Chinese Academy of Sciences Institute of Chemistry CHINA
| | - Yun Huang
- Chinese Academy of Sciences Institute of Chemistry CHINA
| | - Bin Wang
- Chinese Academy of Sciences Institute of Chemistry CHINA
| | - Lili Ma
- Hebei University College of Chemistry and Environmental Science CHINA
| | - Johannes Karges
- University of California San Diego Chemistry and Biochemistry 9500 Gilman Dr 92093 San Diego UNITED STATES
| | - Haihua Xiao
- Chinese Academy of Sciences Institute of Chemistry CHINA
| |
Collapse
|
7
|
Truong D, Lam NYS, Kamalov M, Riisom M, Jamieson SMF, Harris PWR, Brimble MA, Metzler-Nolte N, Hartinger C. A solid support-based synthetic strategy for the site-selective functionalization of peptides with organometallic half-sandwich moieties. Chemistry 2021; 28:e202104049. [PMID: 34967066 DOI: 10.1002/chem.202104049] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/10/2021] [Indexed: 11/11/2022]
Abstract
The number of donor atoms available on peptides that can competitively coordinate to metal centers renders the site-selective generation of advanced metal-peptide conjugates in high purity a challenging venture. Herein, we present a transmetalation-based synthetic approach on solid support in which an imidazolium proligand can be used to selectively anchor a range of transition metal half-sandwich complexes onto peptides in the presence of multiple coordinative motifs. Amenable to solid support, a range of N-terminus and/or lysine conjugated metal-peptide conjugates were obtained in high purity after cleavage from the resin. The metalated peptides were evaluated for their anticancer properties against human cancer cell lines. While no cytotoxic activity was observed, this platform has the potential to i) provide a pathway to site-selective peptide labelling, ii) be explored as a biorthogonal handle and/or iii) generate a new strategy for ligand design in transition metal catalysts.
Collapse
Affiliation(s)
- Dianna Truong
- University of Auckland, School of Chemical Sciences, NEW ZEALAND
| | - Nelson Y S Lam
- The Scripps Research Institute, Department of Chemistry, UNITED STATES
| | - Meder Kamalov
- University of Auckland, School of Chemical Sciences, NEW ZEALAND
| | - Mie Riisom
- University of Auckland, School of Chemical Sciences, NEW ZEALAND
| | | | - Paul W R Harris
- University of Auckland, School of Chemical Sciences, NEW ZEALAND
| | | | | | - Christian Hartinger
- University of Auckland, School of Chemical Sciences, 23 Symonds Street, 1010, Auckland, NEW ZEALAND
| |
Collapse
|
8
|
Zuccolo M, Arrighetti N, Perego P, Colombo D. Recent Progresses in Conjugation with Bioactive Ligands to Improve the Anticancer Activity of Platinum Compounds. Curr Med Chem 2021; 29:2566-2601. [PMID: 34365939 DOI: 10.2174/0929867328666210806110857] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/31/2021] [Revised: 06/09/2021] [Accepted: 06/15/2021] [Indexed: 11/22/2022]
Abstract
Platinum (Pt) drugs, including cisplatin, are widely used for the treatment of solid tumors. Despite the clinical success, side effects and occurrence of resistance represent major limitations to the use of clinically available Pt drugs. To overcome these problems, a variety of derivatives have been designed and synthetized. Here, we summarize the recent progress in the development of Pt(II) and Pt(IV) complexes with bioactive ligands. The development of Pt(II) and Pt(IV) complexes with targeting molecules, clinically available agents, and other bioactive molecules is an active field of research. Even if none of the reported Pt derivatives has been yet approved for clinical use, many of these compounds exhibit promising anticancer activities with an improved pharmacological profile. Thus, planning hybrid compounds can be considered as a promising approach to improve the available Pt-based anticancer agents and to obtain new molecular tools to deepen the knowledge of cancer progression and drug resistance mechanisms.
Collapse
Affiliation(s)
- Marco Zuccolo
- Dipartimento di Biotecnologie Mediche e Medicina Traslazionale, Università degli Studi di Milano, Milan. Italy
| | - Noemi Arrighetti
- Molecular Pharmacology Unit, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan. Italy
| | - Paola Perego
- Molecular Pharmacology Unit, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan. Italy
| | - Diego Colombo
- Dipartimento di Biotecnologie Mediche e Medicina Traslazionale, Università degli Studi di Milano, Milan. Italy
| |
Collapse
|
9
|
Intracellular delivery of oxaliplatin conjugate via cell penetrating peptide for the treatment of colorectal carcinoma in vitro and in vivo. Int J Pharm 2021; 606:120904. [PMID: 34293467 DOI: 10.1016/j.ijpharm.2021.120904] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/28/2021] [Revised: 07/06/2021] [Accepted: 07/16/2021] [Indexed: 12/24/2022]
Abstract
Pt-based drugs are one of the main active agents in colorectal cancer treatment. However, drug resistance and dose-dependent side effects are the main barriers that restrict their clinical applications. As an alternative approach to these issues, we designed and synthesized a cell penetrating peptide (CPP) octaarginine-oxaliplatin conjugate that quickly and successfully delivered oxaliplatin into colon cancer cells. The CPP octaarginine is a well-studied cationic peptide that can play a role as a drug delivery vector. In this work, an octaarginine CPP (RRRRRRRR) was conjugated with oxaliplatin via a specific heterobifunctional linker. The in vitro studies showed the conjugate had affinity toward mitochondria inside cells and the MTT assay confirmed that conjugate is active in low micromolar range against colon cancer cells, requiring much lower concentrations than the oxaliplatin alone to reach IC50. More importantly, in the in vivo mouse study, the conjugate effectively inhibited tumor growth and showed considerably high antitumor activity, demonstrating the conjugate can perform well in vivo. This strategy may offer a new approach for designing oxaliplatin derivatives or prodrugs with remarkable therapeutic capabilities.
Collapse
|
10
|
Haseloer A, Lützenburg T, Strache JP, Neudörfl J, Neundorf I, Klein A. Building up Pt II -Thiosemicarbazone-Lysine-sC18 Conjugates. Chembiochem 2021; 22:694-704. [PMID: 32909347 PMCID: PMC7894172 DOI: 10.1002/cbic.202000564] [Citation(s) in RCA: 6] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/12/2020] [Revised: 09/03/2020] [Indexed: 12/12/2022]
Abstract
Three chiral tridentate N^N^S coordinating pyridine-carbaldehyde (S)-N4-(α-methylbenzyl)thiosemicarbazones (HTSCmB) were synthesised along with lysine-modified derivatives. One of them was selected and covalently conjugated to the cell-penetrating peptide sC18 by solid-phase peptide synthesis. The HTSCmB model ligands, the HTSCLp derivatives and the peptide conjugate rapidly and quantitatively form very stable PtII chlorido complexes [Pt(TSC)Cl] when treated with K2 PtCl4 in solution. The Pt(CN) derivatives were obtained from one TSCmB model complex and the peptide conjugate complex through Cl- →CN- exchange. Ligands and complexes were characterised by NMR, IR spectroscopy, HR-ESI-MS and single-crystal XRD. Intriguingly, no decrease in cell viability was observed when testing the biological activity of the lysine-tagged HdpyTSCLp, its sC18 conjugate HdpyTSCL-sC18 or the PtCl and Pt(CN) conjugate complexes in three different cell lines. Thus, given the facile and effective preparation of such Pt-TSC-peptide conjugates, these systems might pave the way for future use in late-stage labelling with Pt radionuclides and application in nuclear medicine.
Collapse
Affiliation(s)
- Alexander Haseloer
- Universität zu Köln, Department für ChemieInstitut für Anorganische ChemieGreinstraße 650939KölnGermany
| | - Tamara Lützenburg
- Universität zu KölnDepartment für Chemie, Institut für BiochemieZülpicher Strasse 47a50674KölnGermany
| | - Joss Pepe Strache
- Universität zu Köln, Department für ChemieInstitut für Anorganische ChemieGreinstraße 650939KölnGermany
| | - Jörg Neudörfl
- Universität zu KölnDepartment für Chemie, Institut für Organische ChemieGreinstraße 450939KölnGermany
| | - Ines Neundorf
- Universität zu KölnDepartment für Chemie, Institut für BiochemieZülpicher Strasse 47a50674KölnGermany
| | - Axel Klein
- Universität zu Köln, Department für ChemieInstitut für Anorganische ChemieGreinstraße 650939KölnGermany
| |
Collapse
|
11
|
Functionalization of new anticancer Pt(II) complex with transferrin receptor binding peptide. Inorganica Chim Acta 2020. [DOI: 10.1016/j.ica.2020.119811] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/27/2022]
|
12
|
Fadzen CM, Wolfe JM, Zhou W, Cho CF, von Spreckelsen N, Hutchinson KT, Lee YC, Chiocca EA, Lawler SE, Yilmaz OH, Lippard SJ, Pentelute BL. A Platinum(IV) Prodrug-Perfluoroaryl Macrocyclic Peptide Conjugate Enhances Platinum Uptake in the Brain. J Med Chem 2020; 63:6741-6747. [PMID: 32410451 DOI: 10.1021/acs.jmedchem.0c00022] [Citation(s) in RCA: 15] [Impact Index Per Article: 3.8] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/02/2023]
Abstract
Effective delivery to the brain limits the development of novel glioblastoma therapies. Here, we introduce conjugation between platinum(IV) prodrugs of cisplatin and perfluoroaryl peptide macrocycles to increase brain uptake. We demonstrate that one such conjugate shows efficacy against glioma stem-like cells. We investigate the pharmacokinetics of this conjugate in mice and show that the amount of platinum in the brain after treatment with the conjugate is 15-fold greater than with cisplatin after 5 h.
Collapse
Affiliation(s)
- Colin M Fadzen
- Department of Chemistry, Massachusetts Institute of Technology, Cambridge, Massachusetts 02139, United States
| | - Justin M Wolfe
- Department of Chemistry, Massachusetts Institute of Technology, Cambridge, Massachusetts 02139, United States
| | - Wen Zhou
- Department of Chemistry, Massachusetts Institute of Technology, Cambridge, Massachusetts 02139, United States.,The Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, Massachusetts 02139, United States
| | - Choi-Fong Cho
- Harvey Cushing Neuro-Oncology Laboratories, Department of Neurosurgery, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts 02115, United States
| | - Niklas von Spreckelsen
- Harvey Cushing Neuro-Oncology Laboratories, Department of Neurosurgery, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts 02115, United States.,Department of Neurosurgery, Center for Neurosurgery, Faculty of Medicine and University Hospital, University of Cologne 50937 Cologne, Germany
| | - Kathryn T Hutchinson
- Harvey Cushing Neuro-Oncology Laboratories, Department of Neurosurgery, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts 02115, United States
| | - Yen-Chun Lee
- Department of Chemistry, Massachusetts Institute of Technology, Cambridge, Massachusetts 02139, United States
| | - E Antonio Chiocca
- Harvey Cushing Neuro-Oncology Laboratories, Department of Neurosurgery, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts 02115, United States
| | - Sean E Lawler
- Harvey Cushing Neuro-Oncology Laboratories, Department of Neurosurgery, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts 02115, United States
| | - Omer H Yilmaz
- The Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, Massachusetts 02139, United States
| | - Stephen J Lippard
- Department of Chemistry, Massachusetts Institute of Technology, Cambridge, Massachusetts 02139, United States
| | - Bradley L Pentelute
- Department of Chemistry, Massachusetts Institute of Technology, Cambridge, Massachusetts 02139, United States.,The Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, Massachusetts 02139, United States
| |
Collapse
|
13
|
Kitteringham E, McKeon AM, O'Dowd P, Devocelle M, Murphy BM, Griffith DM. Synthesis and characterisation of a novel mono functionalisable Pt(IV) oxaliplatin-type complex and its peptide conjugate. Inorganica Chim Acta 2020. [DOI: 10.1016/j.ica.2020.119492] [Citation(s) in RCA: 6] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/17/2022]
|
14
|
Meier-Menches SM, Casini A. Design Strategies and Medicinal Applications of Metal-Peptidic Bioconjugates. Bioconjug Chem 2020; 31:1279-1288. [DOI: 10.1021/acs.bioconjchem.0c00152] [Citation(s) in RCA: 27] [Impact Index Per Article: 6.8] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/17/2022]
Affiliation(s)
- Samuel M. Meier-Menches
- Department of Analytical Chemistry, Faculty of Chemistry, University of Vienna, Waehringer Strasse 38, 1090 Vienna, Austria
| | - Angela Casini
- Chair of Medicinal and Bioinorganic Chemistry, Department of Chemistry, Technical University of Munich, Lichtenbergstrasse 4, 85748 Garching, Germany
| |
Collapse
|
15
|
Ravera M, Gabano E, McGlinchey MJ, Osella D. A view on multi-action Pt(IV) antitumor prodrugs. Inorganica Chim Acta 2019. [DOI: 10.1016/j.ica.2019.04.025] [Citation(s) in RCA: 47] [Impact Index Per Article: 9.4] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/14/2023]
|
16
|
Kenny RG, Marmion CJ. Toward Multi-Targeted Platinum and Ruthenium Drugs-A New Paradigm in Cancer Drug Treatment Regimens? Chem Rev 2019; 119:1058-1137. [PMID: 30640441 DOI: 10.1021/acs.chemrev.8b00271] [Citation(s) in RCA: 398] [Impact Index Per Article: 79.6] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/06/2023]
Abstract
While medicinal inorganic chemistry has been practised for over 5000 years, it was not until the late 1800s when Alfred Werner published his ground-breaking research on coordination chemistry that we began to truly understand the nature of the coordination bond and the structures and stereochemistries of metal complexes. We can now readily manipulate and fine-tune their properties. This had led to a multitude of complexes with wide-ranging biomedical applications. This review will focus on the use and potential of metal complexes as important therapeutic agents for the treatment of cancer. With major advances in technologies and a deeper understanding of the human genome, we are now in a strong position to more fully understand carcinogenesis at a molecular level. We can now also rationally design and develop drug molecules that can either selectively enhance or disrupt key biological processes and, in doing so, optimize their therapeutic potential. This has heralded a new era in drug design in which we are moving from a single- toward a multitargeted approach. This approach lies at the very heart of medicinal inorganic chemistry. In this review, we have endeavored to showcase how a "multitargeted" approach to drug design has led to new families of metallodrugs which may not only reduce systemic toxicities associated with modern day chemotherapeutics but also address resistance issues that are plaguing many chemotherapeutic regimens. We have focused our attention on metallodrugs incorporating platinum and ruthenium ions given that complexes containing these metal ions are already in clinical use or have advanced to clinical trials as anticancer agents. The "multitargeted" complexes described herein not only target DNA but also contain either vectors to enable them to target cancer cells selectively and/or moieties that target enzymes, peptides, and intracellular proteins. Multitargeted complexes which have been designed to target the mitochondria or complexes inspired by natural product activity are also described. A summary of advances in this field over the past decade or so will be provided.
Collapse
Affiliation(s)
- Reece G Kenny
- Centre for Synthesis and Chemical Biology, Department of Chemistry , Royal College of Surgeons in Ireland , 123 St. Stephen's Green , Dublin 2 , Ireland
| | - Celine J Marmion
- Centre for Synthesis and Chemical Biology, Department of Chemistry , Royal College of Surgeons in Ireland , 123 St. Stephen's Green , Dublin 2 , Ireland
| |
Collapse
|
17
|
Sheikh AH, Khalid A, Khan F, Begum A. Fluorescent Gadolinium(III)-Oligopeptide Complexes and Carbon Nanotube Composite as Dual Modality Anticancer Agents. ChemistrySelect 2019. [DOI: 10.1002/slct.201802810] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/16/2023]
Affiliation(s)
- Aasif Hassan Sheikh
- Department of Chemistry; Jamia Hamdard University, New; Delhi - 110062 India
| | - Anam Khalid
- Department of Chemistry; Jamia Hamdard University, New; Delhi - 110062 India
| | - Farah Khan
- Department of Biochemistry; Jamia Hamdard University; New Delhi - 110062 India
| | - Ameerunisha Begum
- Department of Chemistry; Jamia Hamdard University, New; Delhi - 110062 India
| |
Collapse
|
18
|
Ong JX, Lim CSQ, Le HV, Ang WH. A Ratiometric Fluorescent Probe for Cisplatin: Investigating the Intracellular Reduction of Platinum(IV) Prodrug Complexes. Angew Chem Int Ed Engl 2018; 58:164-167. [PMID: 30407697 DOI: 10.1002/anie.201810361] [Citation(s) in RCA: 49] [Impact Index Per Article: 8.2] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/09/2018] [Revised: 10/15/2018] [Indexed: 01/02/2023]
Abstract
The PtIV prodrug strategy has emerged as an excellent alternative to tackle the problems associated with conventional PtII drug therapy. However, there is a lack of tools to study how this new class of PtIV drugs are processed at the cellular level. Herein, we report the first ratiometric probe for cisplatin detection and use it to investigate PtIV anticancer complexes in biological systems. The probe was able to distinguish between cisplatin and its PtIV derivatives, allowing us to probe the intracellular reduction of PtIV prodrug complexes. The correlation between the amount of active PtII species available after intracellular reduction of PtIV complexes and their cytotoxicity and the role glutathione plays in the reduction of PtIV complexes were investigated.
Collapse
Affiliation(s)
- Jun Xiang Ong
- Department of Chemistry, National University of Singapore, 3 Science Drive 3, Singapore, 117543, Singapore
| | - Carine Shu Qing Lim
- Department of Chemistry, National University of Singapore, 3 Science Drive 3, Singapore, 117543, Singapore
| | - Hai Van Le
- Department of Chemistry, National University of Singapore, 3 Science Drive 3, Singapore, 117543, Singapore
| | - Wee Han Ang
- Department of Chemistry, National University of Singapore, 3 Science Drive 3, Singapore, 117543, Singapore.,NUS Graduate School of Integrative Sciences and Engineering, Institution, National University of Singapore, 28 Medical Drive, Singapore, 117456, Singapore
| |
Collapse
|
19
|
Ong JX, Lim CSQ, Le HV, Ang WH. A Ratiometric Fluorescent Probe for Cisplatin: Investigating the Intracellular Reduction of Platinum(IV) Prodrug Complexes. Angew Chem Int Ed Engl 2018. [DOI: 10.1002/ange.201810361] [Citation(s) in RCA: 12] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/10/2022]
Affiliation(s)
- Jun Xiang Ong
- Department of Chemistry; National University of Singapore; 3 Science Drive 3 Singapore 117543 Singapore
| | - Carine Shu Qing Lim
- Department of Chemistry; National University of Singapore; 3 Science Drive 3 Singapore 117543 Singapore
| | - Hai Van Le
- Department of Chemistry; National University of Singapore; 3 Science Drive 3 Singapore 117543 Singapore
| | - Wee Han Ang
- Department of Chemistry; National University of Singapore; 3 Science Drive 3 Singapore 117543 Singapore
- NUS Graduate School of Integrative Sciences and Engineering, Institution; National University of Singapore; 28 Medical Drive Singapore 117456 Singapore
| |
Collapse
|
20
|
Smiłowicz D, Metzler-Nolte N. Synthesis of monofunctional platinum(iv) carboxylate precursors for use in Pt(iv)-peptide bioconjugates. Dalton Trans 2018; 47:15465-15476. [PMID: 30334055 DOI: 10.1039/c8dt03082k] [Citation(s) in RCA: 15] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/19/2022]
Abstract
Herein we present platinum(iv) bioconjugates with polyarginine peptides as prospective prodrug delivery systems. Asymmetrical platinum(iv) complexes 3 were obtained via oxidation of parent platinum(ii) complexes 2 with N-bromosuccinimide (NBS) in the presence of succinic anhydride. The combination of these two oxidation reagents furnishes the platinum(iv) environment with two different axial ligands, one of which bears a free carboxylic acid. All platinum(ii) and (iv) compounds were characterized by FT-IR, ESI-MS, HPLC, 1H-, 13C- and 195Pt-NMR. Standard solid-phase peptide chemistry was used for the synthesis of polyarginine (R9) peptides. Coupling of the platinum complexes with peptides N-terminally afforded peptide monoconjugates, which were purified by semi-preparative HPLC and characterized by analytical HPLC and ESI-MS. Platinum(iv)-peptide bioconjugates as well as platinum(ii) and platinum(iv) complexes were tested as cytotoxic agents against two different human cancer cell lines (MCF-7, HepG2) and normal human fibroblasts cell lines (GM5657T). Preliminary in vitro data showed that all platinum(iv) complexes exhibit lower activity than their platinum(ii) precursors towards most cell lines. Interestingly, in the case of HepG2 cells, the Pt(iv)-(R)9-G-A-L bioconjugate (4a) showed even higher activity compared to the non-targeting platinum(iv) parent compound.
Collapse
Affiliation(s)
- Dariusz Smiłowicz
- Inorganic Chemistry I - Bioinorganic Chemistry, Faculty of Chemistry and Biochemistry, Ruhr-University Bochum, Universitätsstraße 150, 44801 Bochum, Germany.
| | | |
Collapse
|
21
|
Platinum(II)-glutamic acid dendrimer conjugates: Synthesis, characterization, DFT calculation, conformational analysis and catalytic properties. Inorganica Chim Acta 2018. [DOI: 10.1016/j.ica.2017.12.022] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/19/2022]
|
22
|
Abstract
In this manuscript we focus on Pt(iv) anticancer prodrugs. We explore the main working hypotheses for the design of effective Pt(iv) prodrugs and note the exceptions to the common assumptions that are prevalent in the field. Special attention was devoted to the emerging class of "dual action" Pt(iv) prodrugs, where bioactive ligands are conjugated to the axial positions of platinum in order to obtain orthogonal or complementary effects that will increase the efficacy of killing the cancer cells. We discuss the rationale behind the design of the "dual action" prodrugs and the results of the pharmacological studies obtained. Simultaneous release of two bioactive moieties inside the cancer cells often triggers several processes that together determine the fate of the cell. Pt(iv) complexes provide many opportunities for applying new concepts in targeting, synergistic cell killing and exploiting novel nanodelivery systems.
Collapse
Affiliation(s)
- Dan Gibson
- Institute of Drug Research, School of Pharmacy, The Hebrew University, Jerusalem, Israel.
| |
Collapse
|
23
|
Basu U, Banik B, Wen R, Pathak RK, Dhar S. The Platin-X series: activation, targeting, and delivery. Dalton Trans 2018; 45:12992-3004. [PMID: 27493131 DOI: 10.1039/c6dt01738j] [Citation(s) in RCA: 76] [Impact Index Per Article: 12.7] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/14/2022]
Abstract
Anticancer platinum (Pt) complexes have long been considered to be one of the biggest success stories in the history of medicinal inorganic chemistry. Yet there remains the hunt for the "magic bullet" which can satisfy the requirements of an effective chemotherapeutic drug formulation. Pt(iv) complexes are kinetically more inert than the Pt(ii) congeners and offer the opportunity to append additional functional groups/ligands for prodrug activation, tumor targeting, or drug delivery. The ultimate aim of functionalization is to enhance the tumor selective action and attenuate systemic toxicity of the drugs. Moreover, an increase in cellular accumulation to surmount the resistance of the tumor against the drugs is also of paramount importance in drug development and discovery. In this review, we will address the attempts made in our lab to develop Pt(iv) prodrugs that can be activated and delivered using targeted nanotechnology-based delivery platforms.
Collapse
Affiliation(s)
- Uttara Basu
- NanoTherapeutics Research Laboratory, Department of Chemistry, University of Georgia, Athens, GA 30602, USA
| | - Bhabatosh Banik
- NanoTherapeutics Research Laboratory, Department of Chemistry, University of Georgia, Athens, GA 30602, USA
| | - Ru Wen
- NanoTherapeutics Research Laboratory, Department of Chemistry, University of Georgia, Athens, GA 30602, USA
| | - Rakesh K Pathak
- NanoTherapeutics Research Laboratory, Department of Chemistry, University of Georgia, Athens, GA 30602, USA
| | - Shanta Dhar
- NanoTherapeutics Research Laboratory, Department of Chemistry, University of Georgia, Athens, GA 30602, USA
| |
Collapse
|
24
|
Wlodarczyk MT, Dragulska SA, Camacho-Vanegas O, Dottino PR, Jarzęcki AA, Martignetti JA, Mieszawska AJ. Platinum (II) complex-nuclear localization sequence peptide hybrid for overcoming platinum resistance in cancer therapy. ACS Biomater Sci Eng 2018; 4:463-467. [PMID: 32042890 DOI: 10.1021/acsbiomaterials.7b00921] [Citation(s) in RCA: 14] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/14/2023]
Abstract
Platinum therapy represents first line of treatment in many malignancies but its high systemic toxicity limits the therapeutic dosage. Herein, we report the synthesis of carboplatin-like complexes with azide and alkyne functional groups and the formation of a platinum (II) - nuclear localization sequence peptide (Pt-NLS) hybrid to improve the import of platinum (II) complexes directly into the cell's nucleus. The Pt-NLS hybrid successfully enters cells and their nuclei, forming Pt-induced nuclear lesions. The in vitro efficacy of Pt-NLS is high, superior to native carboplatin at the same concentration. The methodology used is simple and cost-effective and most importantly can easily be extended to load the Pt (II) onto other supports, opening new possibilities for enhanced delivery of Pt (II) therapy.
Collapse
Affiliation(s)
- Marek T Wlodarczyk
- Department of Chemistry, Brooklyn College, The City University of New York, 2900 Bedford Avenue, Brooklyn NY 11210.,Ph.D. Program in Chemistry, The Graduate Center of the City University of New York, New York, NY 10016
| | - Sylwia A Dragulska
- Department of Chemistry, Brooklyn College, The City University of New York, 2900 Bedford Avenue, Brooklyn NY 11210
| | - Olga Camacho-Vanegas
- Department of Genetics and Genomic Sciences, Icahn School of Medicine at Mount Sinai, 1425 Madison Avenue, New York, NY 10029
| | - Peter R Dottino
- Department of Obstetrics, Gynecology, and Reproductive Sciences, Icahn sSchool of Medicine at Mount Sinai, 1425 Madison Avenue, New York, NY 10029
| | - Andrzej A Jarzęcki
- Department of Chemistry, Brooklyn College, The City University of New York, 2900 Bedford Avenue, Brooklyn NY 11210
| | - John A Martignetti
- Department of Genetics and Genomic Sciences, Icahn School of Medicine at Mount Sinai, 1425 Madison Avenue, New York, NY 10029.,Laboratory for Translational Research, Western Connecticut Health Network, 131 West Street, Danbury, CT 06810
| | - Aneta J Mieszawska
- Department of Chemistry, Brooklyn College, The City University of New York, 2900 Bedford Avenue, Brooklyn NY 11210
| |
Collapse
|
25
|
Kumbhakonam S, Vellaisamy K, Saroj S, Venkatesan N, D. K, Kannoth Manheri M. Serine- and threonine-derived diamine equivalents for site-specific incorporation of platinum centers in peptides, and the anticancer potential of these conjugates. NEW J CHEM 2018. [DOI: 10.1039/c7nj03999a] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/21/2022]
Abstract
A modular strategy that gives access to a library of peptide–Pt conjugates and their anticancer potential is presented.
Collapse
Affiliation(s)
| | | | - Soumya Saroj
- Department of Chemistry
- Indian Institute of Technology Madras
- Chennai
- India
| | - Nalini Venkatesan
- Department of Biotechnology
- Indian Institute of Technology Madras
- Chennai
- India
| | - Karunagaran D.
- Department of Biotechnology
- Indian Institute of Technology Madras
- Chennai
- India
| | | |
Collapse
|
26
|
Medrano MA, Morais M, Ferreira VFC, Correia JDG, Paulo A, Santos I, Navarro-Ranninger C, Valdes AA, Casini A, Mendes F, Quiroga AG. Nonconventionaltrans-Platinum Complexes Functionalized with RDG Peptides: Chemical and Cytototoxicity Studies. Eur J Inorg Chem 2017. [DOI: 10.1002/ejic.201700072] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022]
Affiliation(s)
- Maria Angeles Medrano
- IadChem. and Departamento de Química Inorgánica; Universidad Autonoma de Madrid; 28049 Madrid Spain
| | - Maurício Morais
- Centro de Ciências e Tecnologias Nucleares; Instituto Superior Técnico; Universidade de Lisboa; Estrada Nacional 10 (km 139,7) 2695-066 Bobadela LRS Portugal
| | - Vera F. C. Ferreira
- Centro de Ciências e Tecnologias Nucleares; Instituto Superior Técnico; Universidade de Lisboa; Estrada Nacional 10 (km 139,7) 2695-066 Bobadela LRS Portugal
| | - João D. G. Correia
- Centro de Ciências e Tecnologias Nucleares; Instituto Superior Técnico; Universidade de Lisboa; Estrada Nacional 10 (km 139,7) 2695-066 Bobadela LRS Portugal
| | - António Paulo
- Centro de Ciências e Tecnologias Nucleares; Instituto Superior Técnico; Universidade de Lisboa; Estrada Nacional 10 (km 139,7) 2695-066 Bobadela LRS Portugal
| | - Isabel Santos
- Centro de Ciências e Tecnologias Nucleares; Instituto Superior Técnico; Universidade de Lisboa; Estrada Nacional 10 (km 139,7) 2695-066 Bobadela LRS Portugal
| | - Carmen Navarro-Ranninger
- IadChem. and Departamento de Química Inorgánica; Universidad Autonoma de Madrid; 28049 Madrid Spain
| | - Amparo Alvarez Valdes
- IadChem. and Departamento de Química Inorgánica; Universidad Autonoma de Madrid; 28049 Madrid Spain
| | - Angela Casini
- School of Chemistry; Instituto Superior Técnico; Cardiff University; Park Place CF10 3AT Cardiff United Kingdom
| | - Filipa Mendes
- Centro de Ciências e Tecnologias Nucleares; Instituto Superior Técnico; Universidade de Lisboa; Estrada Nacional 10 (km 139,7) 2695-066 Bobadela LRS Portugal
| | - Adoración G. Quiroga
- IadChem. and Departamento de Química Inorgánica; Universidad Autonoma de Madrid; 28049 Madrid Spain
| |
Collapse
|
27
|
Kenny RG, Chuah SW, Crawford A, Marmion CJ. Platinum(IV) Prodrugs - A Step Closer to Ehrlich's Vision? Eur J Inorg Chem 2017. [DOI: 10.1002/ejic.201601278] [Citation(s) in RCA: 105] [Impact Index Per Article: 15.0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/27/2022]
Affiliation(s)
- Reece G. Kenny
- Department of Pharmaceutical & Medicinal Chemistry; Royal College of Surgeons in Ireland; 123 St. Stephen's Green 2 Dublin Ireland
| | - Su Wen Chuah
- Department of Pharmaceutical & Medicinal Chemistry; Royal College of Surgeons in Ireland; 123 St. Stephen's Green 2 Dublin Ireland
| | - Alanna Crawford
- Department of Pharmaceutical & Medicinal Chemistry; Royal College of Surgeons in Ireland; 123 St. Stephen's Green 2 Dublin Ireland
| | - Celine J. Marmion
- Department of Pharmaceutical & Medicinal Chemistry; Royal College of Surgeons in Ireland; 123 St. Stephen's Green 2 Dublin Ireland
| |
Collapse
|
28
|
McKeon AM, Noonan J, Devocelle M, Murphy BM, Griffith DM. Platinum(iv) oxaliplatin–peptide conjugates targeting memHsp70+ phenotype in colorectal cancer cells. Chem Commun (Camb) 2017; 53:11318-11321. [DOI: 10.1039/c7cc04764a] [Citation(s) in RCA: 20] [Impact Index Per Article: 2.9] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/21/2022]
Abstract
Novel Pt(iv) tumour penetrating peptide (TPP) conjugates are reported.
Collapse
Affiliation(s)
- A. M. McKeon
- Department of Pharmaceutical & Medicinal Chemistry, Royal College of Surgeons in Ireland
- Dublin 2
- Ireland
| | - J. Noonan
- Department of Physiology & Medical Physics, Royal College of Surgeons in Ireland
- D2
- Ireland
| | - M. Devocelle
- Department of Pharmaceutical & Medicinal Chemistry, Royal College of Surgeons in Ireland
- Dublin 2
- Ireland
| | - B. M. Murphy
- Department of Physiology & Medical Physics, Royal College of Surgeons in Ireland
- D2
- Ireland
| | - D. M. Griffith
- Department of Pharmaceutical & Medicinal Chemistry, Royal College of Surgeons in Ireland
- Dublin 2
- Ireland
| |
Collapse
|
29
|
May glutamine addiction drive the delivery of antitumor cisplatin-based Pt(IV) prodrugs? J Inorg Biochem 2016; 167:27-35. [PMID: 27898344 DOI: 10.1016/j.jinorgbio.2016.11.024] [Citation(s) in RCA: 22] [Impact Index Per Article: 2.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/08/2016] [Revised: 11/09/2016] [Accepted: 11/16/2016] [Indexed: 12/11/2022]
Abstract
A small series of Pt(IV) prodrugs containing Gln-like (Gln=glutamine) axial ligands has been designed with the aim to take advantage of the increased demand of Gln showed by some cancer cells (glutamine addiction). In complex 4 the Gln, linked through the α-carboxylic group is recognized by the Gln transporters, in particular by the solute carrier transporter SLC1A5. All compounds showed cellular accumulation, as well as antiproliferative activity, related to their lipophilicity, as already demonstrated for the majority of Pt(IV) prodrugs, that enter cells mainly by passive diffusion. On the contrary, when the Gln concentration in cell medium is near or lower to the physiological value, complex 4 acts as a Trojan horse: it enters SLC1A5-overexpressing cells, where, upon reduction, it releases the active metabolite cisplatin and the Gln-containing ligand, thus preventing any possible extrusion by the L-type amino acid transporter LAT1. This selective mechanism could decrease off-target accumulation of 4 and, consequently, Pt-associated side-effects.
Collapse
|
30
|
Albada B, Metzler-Nolte N. Organometallic–Peptide Bioconjugates: Synthetic Strategies and Medicinal Applications. Chem Rev 2016; 116:11797-11839. [DOI: 10.1021/acs.chemrev.6b00166] [Citation(s) in RCA: 149] [Impact Index Per Article: 18.6] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/24/2023]
Affiliation(s)
- Bauke Albada
- Laboratory of Organic Chemistry, Wageningen University & Research, Stippeneng 4, 6708 WE Wageningen, The Netherlands
| | - Nils Metzler-Nolte
- Inorganic
Chemistry I − Bioinorganic Chemistry, Ruhr University Bochum, Universitätsstrasse 150, 44780-D Bochum, Germany
| |
Collapse
|
31
|
Johnstone TC, Suntharalingam K, Lippard SJ. The Next Generation of Platinum Drugs: Targeted Pt(II) Agents, Nanoparticle Delivery, and Pt(IV) Prodrugs. Chem Rev 2016; 116:3436-86. [PMID: 26865551 PMCID: PMC4792284 DOI: 10.1021/acs.chemrev.5b00597] [Citation(s) in RCA: 1660] [Impact Index Per Article: 207.5] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/07/2023]
Abstract
The platinum drugs, cisplatin, carboplatin, and oxaliplatin, prevail in the treatment of cancer, but new platinum agents have been very slow to enter the clinic. Recently, however, there has been a surge of activity, based on a great deal of mechanistic information, aimed at developing nonclassical platinum complexes that operate via mechanisms of action distinct from those of the approved drugs. The use of nanodelivery devices has also grown, and many different strategies have been explored to incorporate platinum warheads into nanomedicine constructs. In this Review, we discuss these efforts to create the next generation of platinum anticancer drugs. The introduction provides the reader with a brief overview of the use, development, and mechanism of action of the approved platinum drugs to provide the context in which more recent research has flourished. We then describe approaches that explore nonclassical platinum(II) complexes with trans geometry or with a monofunctional coordination mode, polynuclear platinum(II) compounds, platinum(IV) prodrugs, dual-threat agents, and photoactivatable platinum(IV) complexes. Nanoparticles designed to deliver platinum(IV) complexes will also be discussed, including carbon nanotubes, carbon nanoparticles, gold nanoparticles, quantum dots, upconversion nanoparticles, and polymeric micelles. Additional nanoformulations, including supramolecular self-assembled structures, proteins, peptides, metal-organic frameworks, and coordination polymers, will then be described. Finally, the significant clinical progress made by nanoparticle formulations of platinum(II) agents will be reviewed. We anticipate that such a synthesis of disparate research efforts will not only help to generate new drug development ideas and strategies, but also will reflect our optimism that the next generation of approved platinum cancer drugs is about to arrive.
Collapse
Affiliation(s)
- Timothy C Johnstone
- Department of Chemistry, Massachusetts Institute of Technology , Cambridge, Massachusetts 02139, United States
| | | | - Stephen J Lippard
- Department of Chemistry, Massachusetts Institute of Technology , Cambridge, Massachusetts 02139, United States
| |
Collapse
|
32
|
Furrer J, Süss-Fink G. Thiolato-bridged dinuclear arene ruthenium complexes and their potential as anticancer drugs. Coord Chem Rev 2016. [DOI: 10.1016/j.ccr.2015.10.007] [Citation(s) in RCA: 78] [Impact Index Per Article: 9.8] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/12/2023]
|
33
|
Soler M, Feliu L, Planas M, Ribas X, Costas M. Peptide-mediated vectorization of metal complexes: conjugation strategies and biomedical applications. Dalton Trans 2016; 45:12970-82. [DOI: 10.1039/c5dt04529k] [Citation(s) in RCA: 33] [Impact Index Per Article: 4.1] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/02/2023]
Abstract
The rich chemical and structural versatility of transition metal complexes provides numerous novel paths to be pursued in the design of molecules that exert particular chemical or physicochemical effects that could operate over specific biological targets.
Collapse
Affiliation(s)
- Marta Soler
- QBIS–CAT Research Group
- Institut de Química Computacional i Catàlisi (IQCC) and Departament de Química
- Universitat de Girona
- E-17071 Girona
- Spain
| | - Lidia Feliu
- LIPPSO
- Departament de Química
- Universitat de Girona
- E-17071 Girona
- Spain
| | - Marta Planas
- LIPPSO
- Departament de Química
- Universitat de Girona
- E-17071 Girona
- Spain
| | - Xavi Ribas
- QBIS–CAT Research Group
- Institut de Química Computacional i Catàlisi (IQCC) and Departament de Química
- Universitat de Girona
- E-17071 Girona
- Spain
| | - Miquel Costas
- QBIS–CAT Research Group
- Institut de Química Computacional i Catàlisi (IQCC) and Departament de Química
- Universitat de Girona
- E-17071 Girona
- Spain
| |
Collapse
|
34
|
Trastuzumab-mediated selective delivery for platinum drug to HER2-positive breast cancer cells. Anticancer Drugs 2015; 26:957-63. [PMID: 26186063 DOI: 10.1097/cad.0000000000000272] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
Abstract
Oxaliplatin is used widely as an anticancer drug for clinical treatment. However, its applications are limited because of its poor selectivity. In this work, we described the design, synthesis, and characterization of conjugates combining trastuzumab with a platinum (IV) analog of oxaliplatin, in which the trastuzumab acted as an active targeting agent for HER2-positive cancer cells. Indirect enzyme-linked immunosorbent assay and immunofluorescence study indicated the platinum (IV)-trastuzumab conjugates retained specific binding activity to HER2 overexpressed SK-BR-3 cells. In the presence of ascorbic acid, platinum (IV)-trastuzumab conjugates were reduced to platinum (II) analogs, which could bind to and unwind PUC19 DNA in a manner similar to oxaliplatin. The cytotoxic study was tested on three breast cell lines: SK-BR-3, MCF-7, and MDA-MB-231. Platinum (IV)-trastuzumab conjugates showed promising antiproliferative activity against SK-BR-3 cells, but significantly decreased the inhibition to MDA-MB-231 and MCF-7 cells. The flow cytometric analysis showed that the conjugates arrested the cell cycle mainly at the G2/M phase and killed the cells through an apoptotic pathway.
Collapse
|
35
|
Shaili E, Fernández-Giménez M, Rodríguez-Astor S, Gandioso A, Sandín L, García-Vélez C, Massaguer A, Clarkson GJ, Woods JA, Sadler PJ, Marchán V. A Photoactivatable Platinum(IV) Anticancer Complex Conjugated to the RNA Ligand Guanidinoneomycin. Chemistry 2015; 21:18474-86. [PMID: 26662220 DOI: 10.1002/chem.201502373] [Citation(s) in RCA: 26] [Impact Index Per Article: 2.9] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/19/2015] [Indexed: 11/07/2022]
Abstract
A photoactivatable platinum(IV) complex, trans,trans,trans-[Pt(N3 )2 (OH)(succ)(py)2 ] (succ=succinylate, py=pyridine), has been conjugated to guanidinoneomycin to study the effect of this guanidinum-rich compound on the photoactivation, intracellular accumulation and phototoxicity of the pro-drug. Surprisingly, trifluoroacetic acid treatment causes the replacement of an azido ligand and the axial hydroxide ligand by trifluoroacetate, as shown by NMR spectroscopy, MS and X-ray crystallography. Photoactivation of the platinum-guanidinoneomycin conjugate in the presence of 5'-guanosine monophosphate (5'-GMP) led to the formation of trans-[Pt(N3 )(py)2 (5'-GMP)](+) , as does the parent platinum(IV) complex. Binding of the platinum(II) photoproduct {PtN3 (py)2 }(+) to guanine nucleobases in a short single-stranded oligonucleotide was also observed. Finally, cellular uptake studies showed that guanidinoneomycin conjugation improved the intracellular accumulation of the platinum(IV) pro-drug in two cancer cell lines, particularly in SK-MEL-28 cells. Notably, the higher phototoxicity of the conjugate in SK-MEL-28 cells than in DU-145 cells suggests a degree of selectivity towards the malignant melanoma cell line.
Collapse
Affiliation(s)
- Evyenia Shaili
- Department of Chemistry, University of Warwick, Warwick, CV4 7AL, Coventry (UK)
| | - Marta Fernández-Giménez
- Departament de Química Orgànica and IBUB, Universitat de Barcelona, Martí i Franquès 1-11, 08028, Barcelona (Spain)
| | - Savina Rodríguez-Astor
- Departament de Química Orgànica and IBUB, Universitat de Barcelona, Martí i Franquès 1-11, 08028, Barcelona (Spain)
| | - Albert Gandioso
- Departament de Química Orgànica and IBUB, Universitat de Barcelona, Martí i Franquès 1-11, 08028, Barcelona (Spain)
| | - Lluís Sandín
- Departament de Química Orgànica and IBUB, Universitat de Barcelona, Martí i Franquès 1-11, 08028, Barcelona (Spain)
| | - Carlos García-Vélez
- Departament de Química Orgànica and IBUB, Universitat de Barcelona, Martí i Franquès 1-11, 08028, Barcelona (Spain)
| | - Anna Massaguer
- Departament de Biologia, Universitat de Girona, Campus Montilivi, 17071, Girona (Spain)
| | - Guy J Clarkson
- Department of Chemistry, University of Warwick, Warwick, CV4 7AL, Coventry (UK)
| | - Julie A Woods
- Photobiology Unit, Department of Dermatology, Ninewells Hospital, Dundee, DD1 9SY (UK)
| | - Peter J Sadler
- Department of Chemistry, University of Warwick, Warwick, CV4 7AL, Coventry (UK).
| | - Vicente Marchán
- Departament de Química Orgànica and IBUB, Universitat de Barcelona, Martí i Franquès 1-11, 08028, Barcelona (Spain).
| |
Collapse
|
36
|
Gabano E, Ravera M, Tinello S, Osella D. Synthesis of PtIV-Biomolecule Conjugates through Click Chemistry. Eur J Inorg Chem 2015. [DOI: 10.1002/ejic.201501066] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/01/2023]
|
37
|
Target-selective delivery and activation of platinum-based anticancer agents. Future Med Chem 2015; 7:911-27. [DOI: 10.4155/fmc.15.37] [Citation(s) in RCA: 14] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/21/2022] Open
|
38
|
Maschke M, Grohmann J, Nierhaus C, Lieb M, Metzler-Nolte N. Peptide Bioconjugates of Electron-Poor Metallocenes: Synthesis, Characterization, and Anti-Proliferative Activity. Chembiochem 2015; 16:1333-42. [DOI: 10.1002/cbic.201500060] [Citation(s) in RCA: 14] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/03/2015] [Indexed: 12/16/2022]
|
39
|
Huang R, Wang Q, Zhang X, Zhu J, Sun B. Trastuzumab-cisplatin conjugates for targeted delivery of cisplatin to HER2-overexpressing cancer cells. Biomed Pharmacother 2015; 72:17-23. [DOI: 10.1016/j.biopha.2015.03.004] [Citation(s) in RCA: 12] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/06/2014] [Accepted: 03/25/2015] [Indexed: 10/23/2022] Open
|
40
|
Giannini F, Bartoloni M, Paul LEH, Süss-Fink G, Reymond JL, Furrer J. Cytotoxic peptide conjugates of dinuclear arene ruthenium trithiolato complexes. MEDCHEMCOMM 2015. [DOI: 10.1039/c4md00433g] [Citation(s) in RCA: 14] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/21/2022]
Abstract
Novel dinuclear arene ruthenium trithiolato complexes containing a water-soluble peptide moiety in one of the three thiolato bridges were designed and evaluated against A2780 human ovarian cancer cells and against their cisplatin-resistant mutant A2780cisR.
Collapse
Affiliation(s)
- Federico Giannini
- Departement für Chemie und Biochemie
- Universität Bern
- CH-3012 Bern
- Switzerland
| | - Marco Bartoloni
- Departement für Chemie und Biochemie
- Universität Bern
- CH-3012 Bern
- Switzerland
| | - Lydia E. H. Paul
- Departement für Chemie und Biochemie
- Universität Bern
- CH-3012 Bern
- Switzerland
| | - Georg Süss-Fink
- Institut de Chimie
- Université de Neuchâtel
- CH-2000 Neuchâtel
- Switzerland
| | - Jean-Louis Reymond
- Departement für Chemie und Biochemie
- Universität Bern
- CH-3012 Bern
- Switzerland
| | - Julien Furrer
- Departement für Chemie und Biochemie
- Universität Bern
- CH-3012 Bern
- Switzerland
| |
Collapse
|
41
|
Low ML, Maigre L, Dorlet P, Guillot R, Pagès JM, Crouse KA, Policar C, Delsuc N. Conjugation of a New Series of Dithiocarbazate Schiff Base Copper(II) Complexes with Vectors Selected to Enhance Antibacterial Activity. Bioconjug Chem 2014; 25:2269-84. [DOI: 10.1021/bc5004907] [Citation(s) in RCA: 49] [Impact Index Per Article: 4.9] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/07/2023]
Affiliation(s)
- May Lee Low
- Laboratoire des BioMolécules, UMR 7203, CNRS, Université Pierre et Marie Curie, Ecole Normale Supérieure,
Départment de Chimie, 24 rue Lhomond, 75005 Paris, France
- Department
of Chemistry, Universiti Putra Malaysia, 43400 Serdang, Selangor, Malaysia
| | - Laure Maigre
- UMR-MD1, Aix-Marseille Université, IRBA, 27 boulevard Jean Moulin, 13385 Marseille, France
| | - Pierre Dorlet
- Laboratoire
Stress Oxydant et Détoxication, Institute for Integrative Biology
of the Cell (I2BC), Université Paris-Saclay, CEA, CNRS, Bât
532 CEA Saclay, 91191 Gif sur Yvette cedex, France
| | - Régis Guillot
- Institut
de Chimie Moléculaire et des Matériaux d’Orsay, Université Paris-Sud Bât. 420, 91405 Orsay, France
| | - Jean-Marie Pagès
- UMR-MD1, Aix-Marseille Université, IRBA, 27 boulevard Jean Moulin, 13385 Marseille, France
| | - Karen A. Crouse
- Department
of Chemistry, Universiti Putra Malaysia, 43400 Serdang, Selangor, Malaysia
| | - Clotilde Policar
- Laboratoire des BioMolécules, UMR 7203, CNRS, Université Pierre et Marie Curie, Ecole Normale Supérieure,
Départment de Chimie, 24 rue Lhomond, 75005 Paris, France
| | - Nicolas Delsuc
- Laboratoire des BioMolécules, UMR 7203, CNRS, Université Pierre et Marie Curie, Ecole Normale Supérieure,
Départment de Chimie, 24 rue Lhomond, 75005 Paris, France
| |
Collapse
|
42
|
Ravera M, Gabano E, Pelosi G, Fregonese F, Tinello S, Osella D. A new entry to asymmetric platinum(IV) complexes via oxidative chlorination. Inorg Chem 2014; 53:9326-35. [PMID: 25121398 DOI: 10.1021/ic501446b] [Citation(s) in RCA: 61] [Impact Index Per Article: 6.1] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/20/2022]
Abstract
Pt(IV) complexes are usually prepared by oxidation of the corresponding Pt(II) counterparts, typically using hydrogen peroxide or chlorine. A different way to synthesize asymmetrical Pt(IV) compounds is the oxidative chlorination of Pt(II) counterparts with N-chlorosuccinimide. The reaction between cisplatin cis-[PtCl2(NH3)2], carboplatin, cis-[PtCl2(dach)] and cis-[Pt(cbdc)(dach)] (cbdc = cyclobutane-1,1'-dicarboxylato; dach = cyclohexane-1R,2R-diamine) with N-chlorosuccinimide in ethane-1,2-diol was optimized to produce the asymmetric Pt(IV) octahedral complexes [PtA2Cl(glyc)X2] (A2 = 2 NH3 or dach; glyc = 2-hydroxyethanolato; X2 = 2 Cl or cbdc) in high yield and purity. The X-ray crystal structure of the [Pt(cbdc)Cl(dach)(glyc)] complex is also reported. Moreover, the oxidation method proved to be versatile enough to produce other mixed Pt(IV) derivatives varying the reaction medium. The two trichlorido complexes easily undergo a pH-dependent hydrolysis reaction, whereas the dicarboxylato compounds are stable enough to allow further coupling reactions for drug targeting and delivery via the glyc reactive pendant. Therefore, the coupling reaction between the [Pt(cbdc)Cl(dach)(glyc)] and a model carboxylic acid, a model amine, and selectively protected amino acids is reported.
Collapse
Affiliation(s)
- Mauro Ravera
- Dipartimento di Scienze e Innovazione Tecnologica, Università del Piemonte Orientale "A. Avogadro" , Viale T. Michel 11, I-15121 Alessandria, Italy
| | | | | | | | | | | |
Collapse
|
43
|
Wong DYQ, Yeo CHF, Ang WH. Immuno-chemotherapeutic platinum(IV) prodrugs of cisplatin as multimodal anticancer agents. Angew Chem Int Ed Engl 2014; 53:6752-6. [PMID: 24844571 DOI: 10.1002/anie.201402879] [Citation(s) in RCA: 95] [Impact Index Per Article: 9.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/28/2014] [Indexed: 12/22/2022]
Abstract
There is growing consensus that the clinical therapeutic efficacy of some chemotherapeutic agents depends on their off-target immune-modulating effects. Pt anticancer drugs have previously been identified to be potent immunomodulators of both the innate and the adaptive immune system. Nevertheless, there has been little development in the rational design of Pt-based chemotherapeutic agents to exploit their immune-activating capabilities. The FPR1/2 formyl peptide receptors are highly expressed in immune cells, as well as in many metastatic cancers. Herein, we report a rationally designed multimodal Pt(IV) prodrug containing a FPR1/2-targeting peptide that combines chemotherapy with immunotherapy to achieve therapeutic synergy and demonstrate the feasibility of this approach.
Collapse
Affiliation(s)
- Daniel Yuan Qiang Wong
- Department of Chemistry, National University of Singapore, 3 Science Drive 3, Singapore (Singapore)
| | | | | |
Collapse
|
44
|
Wong DYQ, Yeo CHF, Ang WH. Immuno-Chemotherapeutic Platinum(IV) Prodrugs of Cisplatin as Multimodal Anticancer Agents. Angew Chem Int Ed Engl 2014. [DOI: 10.1002/ange.201402879] [Citation(s) in RCA: 27] [Impact Index Per Article: 2.7] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/22/2022]
|
45
|
Wilson JJ, Lippard SJ. Synthetic methods for the preparation of platinum anticancer complexes. Chem Rev 2013; 114:4470-95. [PMID: 24283498 DOI: 10.1021/cr4004314] [Citation(s) in RCA: 487] [Impact Index Per Article: 44.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/21/2022]
Affiliation(s)
- Justin J Wilson
- Department of Chemistry, Massachusetts Institute of Technology , Cambridge, Massachusetts 02139, United States
| | | |
Collapse
|
46
|
Johnstone TC, Wilson JJ, Lippard SJ. Monofunctional and higher-valent platinum anticancer agents. Inorg Chem 2013; 52:12234-49. [PMID: 23738524 PMCID: PMC3818431 DOI: 10.1021/ic400538c] [Citation(s) in RCA: 174] [Impact Index Per Article: 15.8] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/12/2022]
Abstract
Platinum compounds represent one of the great success stories of metals in medicine. Following the serendipitous discovery of the anticancer activity of cisplatin by Rosenberg, a large number of cisplatin variants have been prepared and tested for their ability to kill cancer cells and inhibit tumor growth. These efforts continue today with increased realization that new strategies are needed to overcome issues of toxicity and resistance inherent to treatment by the approved platinum anticancer agents. One approach has been the use of so-called "non-traditional" platinum(II) and platinum(IV) compounds that violate the structure-activity relationships that governed platinum drug-development research for many years. Another is the use of specialized drug-delivery strategies. Here we describe recent developments from our laboratory involving monofunctional platinum(II) complexes together with a historical account of the manner by which we came to investigate these compounds and their relationship to previously studied molecules. We also discuss work carried out using platinum(IV) prodrugs and the development of nanoconstructs designed to deliver them in vivo.
Collapse
Affiliation(s)
- Timothy C. Johnstone
- Department of Chemistry, Massachusetts Institute of Technology, Cambridge, MA, 02139
| | - Justin J. Wilson
- Department of Chemistry, Massachusetts Institute of Technology, Cambridge, MA, 02139
| | - Stephen J. Lippard
- Department of Chemistry, Massachusetts Institute of Technology, Cambridge, MA, 02139
| |
Collapse
|
47
|
Montagner D, Yap SQ, Ang WH. A Fluorescent Probe for Investigating the Activation of Anticancer Platinum(IV) Prodrugs Based on the Cisplatin Scaffold. Angew Chem Int Ed Engl 2013. [DOI: 10.1002/ange.201305734] [Citation(s) in RCA: 10] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/16/2022]
|
48
|
Montagner D, Yap SQ, Ang WH. A fluorescent probe for investigating the activation of anticancer platinum(IV) prodrugs based on the cisplatin scaffold. Angew Chem Int Ed Engl 2013; 52:11785-9. [PMID: 24105908 DOI: 10.1002/anie.201305734] [Citation(s) in RCA: 36] [Impact Index Per Article: 3.3] [Reference Citation Analysis] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/03/2013] [Indexed: 01/28/2023]
Affiliation(s)
- Diego Montagner
- Department of Chemistry, National University of Singapore, 3 Science Drive 3, Singapore (Singapore)
| | | | | |
Collapse
|
49
|
Monney A, Albrecht M. Transition metal bioconjugates with an organometallic link between the metal and the biomolecular scaffold. Coord Chem Rev 2013. [DOI: 10.1016/j.ccr.2012.12.015] [Citation(s) in RCA: 53] [Impact Index Per Article: 4.8] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/21/2022]
|
50
|
Wilson JJ, Lippard SJ. Oxidative Reactivity and Cytotoxic Properties of a Platinum(II) Complex Prepared by Outer-Sphere Amide Bond Coupling. Polyhedron 2013; 58:71-78. [PMID: 24489429 DOI: 10.1016/j.poly.2012.07.097] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/28/2022]
Abstract
Benzyl amine was coupled to the dangling carboxylic acid groups of the platinum(II) complex [Pt(edda)Cl2], where edda = ethylenediamine-N,N'-diacetic acid, to give the diamidetethered complex [Pt(L)Cl2] (1), where L = ethylenediamine-N,N'-bis(N-benzylacetamide). Complex 1 was oxidized with both PhICl2 and Br2. Oxidation with PhICl2 cleanly afforded the tetrachloride complex, [Pt(L)Cl4] (2), whereas oxidation with Br2 gave rise to several mixed halide complexes of the general formula, [Pt(L)ClxBr4-x], where x = 1, 2, or 3. Complexes 1 and 2 were fully characterized by 1H, 13C, and 195Pt NMR spectroscopy, as well as by ESI-MS. These compounds exist as a mixture of diastereomers that arise from the chirality of the two coordinated nitrogen atoms. Crystal structures of 1, 2, and [Pt(L)ClxBry] (3) are reported. Although refined as the tetrabromide complex [Pt(L)Br4], the crystal structure of 3 is a mixture of species with site-occupancy disorder of chloride and bromide ligands. DFT calculations indicate that the two sets of diastereomers of 1 and 2 are effectively thermoneutral, a conclusion that is also supported by the observation of both members of each pair by NMR spectroscopy. The cytotoxicity of 1 and 2 was measured by the MTT assay in HeLa cells and compared to that of cisplatin. Both exhibit IC50 values close to 50 μM and are therefore substantially less toxic than cisplatin, for which the IC50 is 1 μM.
Collapse
Affiliation(s)
- Justin J Wilson
- Department of Chemistry, Massachusetts Institute of Technology, Cambridge, MA 02139, United States
| | - Stephen J Lippard
- Department of Chemistry, Massachusetts Institute of Technology, Cambridge, MA 02139, United States
| |
Collapse
|